UK backs ranibizumab (Lucentis) for new use after Novartis cuts price

LONDON (Reuters) – Britain’s healthcare cost watchdog has given its backing to ranibizumab (Lucentis)
to treat diabetic macular edema after Swiss drugmaker Novartis offered it at a discount to the National Health
Service.
Source: Modern Medicine: Optometry